pharm antiparkinsonian drugs Flashcards
parkinsons
progressive neurodegenerative disease
parkinsons affects
dopamine-producing neurons by having an imbalance of dopamine and ACh
symptoms occur when
80% of dopamine stored in basal ganglia is depleted
symptoms can be controlled when
nerve terminals can uptake dopamine
parkinsons symptoms include
bradykinesia (slow movement)
TRAP- tremor, rigidity, akinesia, postural instability.
dyskinesia
difficulty preforming voluntary movements.
when too much dopamine is present
2 types of dyskinesia
chorea- spasmodic movement in face or limbs
dystonia- abnormal muscle tone leading to abnormal movements
drug therapies aimed at
increasing levels of dopamine and antagonizing ACh
levdopa
precursor for dopamine, allowed in blood-brain barrier (unlike dopamine).
nondopamine dopamine receptor agonist ex
ergot derivative- bromocriptine
bromocriptine
works by direct stimulation of presynaptic receptors in brain. stim production of dopmine in brain and inhibits production of proalctin
bromocriptine adverse effects + use with caution
use with caution with ppl w/ peripheral vascular disease
GI upset, dyskinesias, sleep disturbances
bromocriptine drug interactions
erythromycin and adrenergic drugs
levodopa is a ____ drug
replacement
levodopa action
works presynaptically to increase blood levels of dopamine
___ is given with levodopa
carbidopia
carbdopia action
binds with levodopa, doesnt cross blood brain barrier, helps prevent breakdown in periphery. results in more levodopa in bb barier
levodopa uptake route
taken up by the dopaminergic terminal and converted into dopamine and then neurotransmitter imbalance is controlled.
after 5-10 years of levodopa therapy…
terminals dont work as good, levodopa is not as effective
levodopa adverse effects
confusion, involuntary mvmt, GI distress, hypotension, cardiac arrythmias
levodopa-carbidopa is counterindicated in cases of
angle closure glaucoma
use levodopa-carbidopa with caution when person has
open angle glaucoma
levodopa-carb interactions
pyridoxine, nonselective MAOIs, benzodiazepines, antipsychotics, dietary protein